nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

12.11.2021 | Review Article

Current status and future perspective of radiopharmaceuticals in China

verfasst von: Ji Hu, Hongyu Li, Yanying Sui, Jin Du

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Radiopharmaceuticals are essential components of nuclear medicine and serve as one of the cornerstones of molecular imaging and precision medicine. They provide new means and approaches for early diagnosis and treatment of diseases. After decades of development and hard efforts, a relatively matured radiopharmaceutical production and management system has been established in China with high-quality facilities. This review provides an overview of the current status of radiopharmaceuticals on production and distribution, clinical application, and regulatory supervision and also describes some important advances in research and development and clinical translation of radiopharmaceuticals in the past 10 years. Moreover, some prospects of research and development of radiopharmaceuticals in the near future are discussed.

Nur mit Berechtigung zugänglich

Zhang J, Luo Z. The progress of radioisotope technology and application in China. Engineering Sciences. 2008;6(2):19–31. http://www.cnki.com.cn/Article/CJFDTotal-ENSC200802003.htm. Accessed 8 Nov 2021.

Liang J, Wu Y, Luo Z. Development of radioisotope preparation technology at CIAE. Atomic Energy Science and Technology. 2020;54, Suppl.:177–84 (in Chinese). http://www.aest.org.cn/CN/Y2020/V54/Izengkan/177. Accessed 8 Nov 2021.

Zhang H, Luo S, Liu G, Zhong Z. Isotope technologies in INPC: state of the art and perspective. Journal of Isotopes. 2011;24, Suppl.(Suppl):116–20 (in Chinese). http://www.tws.org.cn/CN/Y2011/V24/I增刊/116. Accessed 8 Nov 2021.

Jia H, Liu B. Radiopharmaceuticals in China: current status and prospects. Radiochim Acta. 2014;102(1–2):53–67. https://doi.org/10.1515/ract-2014-2100.CrossRef

Zhang J, Du J. Preparation of radiopharmaceuticals in china: current status and prospects. Journal of Isotopes. 2019;32(3):178–85 (in Chinese). https://doi.org/10.7538/tws.2019.32.03.0178CrossRef

Chinese Society of Nuclear Medicine. A brief report on the results of the national survey of nuclear medicine in 2020. Chin J Nucl Med Mol Imaging. 2020;40(12):747–9 (in Chinese). http://doi.org/10.3760/cma.j.cn321828-20201109-00403.

Xia Z, Luo Z. Review of the evaluation of radiopharmaceuticals. Chin J Nucl Med Mol Imaging. 2006;26(1):49–50 (in Chinese). http://rs.yiigle.com/CN321828200601/162190.htm. Accessed 8 Nov 2021.

Liang J, Shen Y, Wu Y, Xiang X, Yu N, Guo S, et al. Development of simulated process for medical fission ⁹⁹Mo production using electroplating UO₂ target with low enriched uranium. Journal of Isotopes. 2018;31(3):165–72 (in Chinese). http://www.tws.org.cn/CN/10.7538/tws.2018.31.03.0165.

Luo Z, Wu Y, J L. Methods for production of medical radioisotope ⁹⁹Mo. Journal of Isotopes. 2018;31(3):129–42 (in Chinese). http://www.tws.org.cn/CN/10.7538/tws.2018.31.03.0129.

10.

Huang W, Liang J, Wu Y, Yu N, Xiang X. Investigation on separation of ⁹⁹Mo from low enriched uranium target by Al₂O₃ chromatography. Journal of Isotopes. 2021;34(1):54–60 (in Chinese). http://www.tws.org.cn/CN/10.7538/tws.2021.34.01.0054.

11.

Peng S, Yang Y, Xie X, Qian D. Current status and prospects of reactor produced medical radioisotopes in China. Chin Sci Bull. 2020;65(32):3526–37 (in Chinese). https://doi.org/10.1360/TB-2020-0374.CrossRef

12.

Shen Y, Chen Y, Liang J, Qiao L, Deng X, Li G, et al. Preparation of Ni target for cyclotron-produced ⁶⁴Cu by electrodeposition. Journal of Isotopes. 2013;26(1):38–41 (in Chinese). http://www.tws.org.cn/CN/10.7538/tws.2013.26.01.0038 ..

13.

Chen Y, Liang J, Li G, Deng X, Qiao L, Shen Y, et al. Chemical separation of ⁶⁴Cu from irradiated Ni target by anion exchange method. Journal of Isotopes. 2012;25(3):144–8 (in Chinese). http://www.tws.org.cn/CN/10.7538/tws.2012.25.03.0144. Accessed 8 Nov 2021.

14.

Deng X, Zhao Z, Zhang B, Liu Y, Liu S, Li M, et al. Development of ¹²⁴Xe gas target system for production of high purity ¹²³I. Atomic Energy Science and Technology. 2016;50(07):1324–8 (in Chinese). https://www.cnki.com.cn/Article/CJFDTotal-YZJS201607028.htm . Accessed 8 Nov 2021.

15.

Tang Y, Li S, Yang Y, Chen W, Wei H, Wang G, et al. A simple and convenient method for production of ⁸⁹Zr with high purity. Appl Radiat Isot. 2016;118:326–30. https://doi.org/10.1016/j.apradiso.2016.09.024.CrossRefPubMed

16.

Liu N, Yang Y, Jin J, Lin R, Cao Y, Liao J, et al. Preparation of radioactive isotopes by CS-30 cyclotron and their applications. Journal of Isotopes. 2012;25(3):189–92 (in Chinese). http://www.tws.org.cn/CN/10.7538/tws.2012.25.03.0189.

17.

Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579(7799):421–6. https://doi.org/10.1038/s41586-020-2079-1.CrossRefPubMed

18.

Wu Y, Li L, Wang Z, Shi J, Hu Z, Gao S, et al. Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe ^99mTc-HYNIC-H10F. Eur J Nucl Med Mol Imaging. 2020;47(11):2613–23. https://doi.org/10.1007/s00259-020-04754-6.CrossRefPubMed

19.

Wang C, Chen Y, Hou YN, Liu Q, Zhang D, Zhao H, et al. ImmunoPET imaging of multiple myeloma with [⁶⁸Ga]Ga-NOTA-Nb1053. Eur J Nucl Med Mol Imaging. 2021;48(9):2749–60. https://doi.org/10.1007/s00259-021-05218-1.CrossRefPubMed

20.

Xu M, Guo J, Gu J, Zhang L, Liu Z, Ding L, et al. Preclinical and clinical study on [¹⁸F]DRKXH1: a novel β-amyloid PET tracer for Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05421-0.CrossRefPubMedPubMedCentral

21.

Liu T, Liu C, Zhang Z, Zhang N, Guo X, Xia L, et al. ⁶⁴Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(13):4508-16. https://doi.org/10.1007/s00259-021-05426-9.CrossRefPubMedPubMedCentral

22.

Duan X, Cao Z, Zhu H, Liu C, Zhang X, Zhang J, et al. ⁶⁸Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05486-x.CrossRefPubMed

23.

Ding J, Zhang Y, Wen J, Zhang H, Wang H, Luo Y, et al. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020;47(11):2656–65. https://doi.org/10.1007/s00259-020-04722-0.CrossRefPubMed

24.

Xie Q, Liu T, Ding J, Zhou N, Meng X, Zhu H, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [¹⁸F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [⁶⁸Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021;48(10):3129-40. https://doi.org/10.1007/s00259-021-05249-8.CrossRefPubMedPubMedCentral

25.

You L, Guo Z, Zhang X. Current status and prospects of radiopharmaceuticals for diagnosis. Journal of Isotopes. 2017 30(4):292–306 (in Chinese). http://www.tws.org.cn/CN/Y2017/V30/I4/292. Accessed 8 Nov 2021.

26.

Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer’s disease. Nat Neurosci. 2020;23(10):1183–93. https://doi.org/10.1038/s41593-020-0687-6.CrossRefPubMed

27.

Cui M, Zhou K, Shen L, Deng X. Dihydrazone compounds having high affinity to Aβ protein and Tau protein, derivatives thereof and use thereof. China Patent, CN109704988A, 20190503 (in Chinese). https://www.incopat.com/detail/init2?formerQuery=wE2KAomDT2iaiJrWYUfKOmr4kAd0KKkg&local=zh. Accessed 8 Nov 2021.

28.

Cui M, Wang X, Yu P, Zhang J, Li Z, Zhang X, et al. Synthesis and evaluation of novel ¹⁸F labeled 2-pyridinylbenzoxazole and 2-pyridinylbenzothiazole derivatives as ligands for positron emission tomography (PET) imaging of β-amyloid plaques. J Med Chem. 2012;55(21):9283–96. https://doi.org/10.1021/jm300973k.CrossRefPubMed

29.

Song J, Peng X, Li L, Yang F, Zhang X, Zhang J, et al. Al¹⁸F-NODA benzothiazole derivatives as imaging agents for cerebrovascular amyloid in cerebral amyloid angiopathy. ACS Omega. 2018;3(10):13089–96. https://doi.org/10.1021/acsomega.8b01120.

30.

Yang Y, Wang X, Yang H, Fu H, Zhang J, Zhang X, et al. Synthesis and monkey-PET study of (R)- and (S)-¹⁸F-labeled 2-arylbenzoheterocyclic derivatives as amyloid probes with distinctive in vivo kinetics. Mol Pharm. 2016;13(11):3852–63. https://doi.org/10.1021/acs.molpharmaceut.6b00643.CrossRefPubMed

31.

Song J, Zhang X, Zhao Y, Yang H, Zhang J, Zhang X, et al. (R)- and (S)-¹⁸F-labeled 2-arylbenzofurans with improved pharmacokinetics as β-amyloid imaging probes. Eur J Med Chem. 2017;134:271–80. https://doi.org/10.1016/j.ejmech.2017.03.073.CrossRefPubMed

32.

Li Y, Zhou K, Guo W, Cui M. ¹⁸F-labeled 2-phenylbenzoheterocycles with chiral dihydroxyl side chains as β-amyloid imaging probes. Biorg Med Chem. 2021;29: 115884. https://doi.org/10.1016/j.bmc.2020.115884.CrossRef

33.

Zhou K, Yang F, Li Y, Chen Y, Zhang X, Zhang J, et al. Synthesis and evaluation of fluorine-18 labeled 2-phenylquinoxaline derivatives as potential tau imaging agents. Mol Pharm. 2021;18(3):1176–95. https://doi.org/10.1021/acs.molpharmaceut.0c01078.CrossRefPubMed

34.

Banister SD, Manoli M, Kassiou M. The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET). J Labelled Compd Radiopharmaceut. 2013;56(3–4):215–24. https://doi.org/10.1002/jlcr.3010.CrossRef

35.

He Y, Xie F, Ye J, Deuther-Conrad W, Cui B, Wang L, et al. 1-(4-[¹⁸F]Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine: a novel suitable radioligand with low lipophilicity for imaging σ1 receptors in the brain. J Med Chem. 2017;60(10):4161–72. https://doi.org/10.1021/acs.jmedchem.6b01723.CrossRefPubMed

36.

Ye J, Wang X, Deuther-Conrad W, Zhang J, Li J, Zhang X, et al. Synthesis and evaluation of a ¹⁸F-labeled 4-phenylpiperidine-4-carbonitrile radioligand for σ1 receptor imaging. J Labelled Compd Radiopharmaceut. 2016;59(9):332–9. https://doi.org/10.1002/jlcr.3408.CrossRef

37.

Xie F, Bergmann R, Kniess T, Deuther-Conrad W, Mamat C, Neuber C, et al. ¹⁸F-Labeled 1,4-dioxa-8-azaspiro[4.5]decane derivative: synthesis and biological evaluation of a σ1 receptor radioligand with low lipophilicity as potent tumor imaging agent. J Med Chem. 2015;58(14):5395–407. https://doi.org/10.1021/acs.jmedchem.5b00593.

38.

Tian J, He Y, Deuther-Conrad W, Fu H, Xie F, Zhang Y, et al. Synthesis and evaluation of new 1-oxa-8-azaspiro[4.5]decane derivatives as candidate radioligands for sigma-1 receptors. Biorg Med Chem. 2020;28(14):115560. https://doi.org/10.1016/j.bmc.2020.115560.CrossRef

39.

Jia H, Cai Z, Holden D, He Y, Lin S-f, Li S, et al. Positron emission tomography imaging evaluation of a novel 18F-labeled sigma-1 Receptor radioligand in cynomolgus monkeys. ACS Chem Neurosci. 2020;11(11):1673–81. https://doi.org/10.1021/acschemneuro.0c00171.

40.

Zhao Z-Q, Liu M, Fang W, Liu S. Sulfonyl-Containing boronate caps for optimization of biological properties of ^99mTc(III) Radiotracers [^99mTcCl(CDO)(CDOH)₂B-R] (CDOH₂ = Cyclohexanedione Dioxime). J Med Chem. 2018;61(1):319–28. https://doi.org/10.1021/acs.jmedchem.7b01412.CrossRefPubMed

41.

Xi X, Wang L, Hsu B, Zhao Z, Liu S, Fang W. ^99mTc-3SPboroxime: a neutral ^99mTc(III) radiotracer with high heart uptake and long myocardial retention. J Nucl Cardiol. 2020. https://doi.org/10.1007/s12350-020-02087-3.CrossRefPubMed

42.

Mou T, Zhao Z, You L, Li Y, Wang Q, Fang W, et al. Synthesis and evaluation of ¹⁸F-labeled pyridaben analogues for myocardial perfusion imaging in mice, rats and chinese mini-swine. Sci Rep. 2016;6(1):33450. https://doi.org/10.1038/srep33450.CrossRefPubMedPubMedCentral

43.

Emmett L. Changing the goal posts: prostate-specific membrane antigen targeted theranostics in prostate cancer. Semin Oncol Nurs. 2020;36(4): 151052. https://doi.org/10.1016/j.soncn.2020.151052.CrossRefPubMed

44.

Duan X, Liu F, Kwon H, Byun Y, Minn I, Cai X, et al. (S)-3-(Carboxyformamido)-2-(3-(carboxymethyl)ureido)propanoic acid as a novel PSMA targeting scaffold for prostate cancer imaging. J Med Chem. 2020;63(7):3563–76. https://doi.org/10.1021/acs.jmedchem.9b02031.

45.

Liu C, Zhu Y, Su H, Xu X, Zhang Y, Song S, et al. Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer. Cancer Med. 2020;9(10):3278–86. https://doi.org/10.1002/cam4.2964.CrossRefPubMedPubMedCentral

46.

Zhang X, Wu Y, Zeng Q, Xie T, Yao S, Zhang J, et al. Synthesis, preclinical evaluation, and first-in-human PET study of quinoline-containing PSMA tracers with decreased renal excretion. J Med Chem. 2021;64(7):4179–95. https://doi.org/10.1021/acs.jmedchem.1c00117.

47.

Sani S, Messe M, Fuchs Q, Pierrevelcin M, Laquerriere P, Entz-Werle N, et al. Biological relevance of RGD-integrin subtype-specific ligands in cancer. ChemBioChem. 2021;22(7):1151–60. https://doi.org/10.1002/cbic.202000626.CrossRefPubMed

48.

Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, et al. Pilot prospective evaluation of ¹⁸F-alfatide II for detection of skeletal metastases. Theranostics. 2015;5(10):1115–21. https://www.thno.org/v05p1115.htm. Accesssed 8 Nov 2021.

49.

Feng X, Wang Y, Lu D, Xu X, Zhou X, Zhang H, et al. Clinical translation of a ⁶⁸Ga-labeled integrin α_vβ₆-targeting cyclic radiotracer for PET imaging of pancreatic cancer. J Nucl Med. 2020;61(10)1461-7. https://doi.org/10.2967/jnumed.119.237347.

50.

Ma H, Liu S, Zhang Z, Tang G, Yuan G, Zhao J, et al. Preliminary biological evaluation of ⁶⁸Ga-labeled cyclic RGD dimer as an integrin α_vβ₃-targeting radiotracer for tumor PET imaging. J Radioanal Nucl Chem. 2019;321(3):857–65. https://doi.org/10.1007/s10967-019-06654-y.CrossRef

51.

Yu X, Wu Y, Liu H, Gao L, Sun X, Zhang C, et al. Small-animal SPECT/CT of the Progression and recovery of rat liver fibrosis by using an integrin α_vβ₃–targeting radiotracer. Radiology. 2015;279(2):502–12. https://doi.org/10.1148/radiol.2015150090.CrossRefPubMed

52.

Gao S, Jia B, Feng G, Dong C, Du H, Bai L, et al. First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer. Signal Transduct Target Ther. 2020;5(1):147. https://doi.org/10.1038/s41392-020-00266-9.CrossRefPubMedPubMedCentral

53.

Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–51. https://doi.org/10.1016/S1470-2045(16)30406-5.CrossRefPubMedPubMedCentral

54.

Xing Y, Chand G, Liu C, Cook GJR, O’Doherty J, Zhao L, et al. Early Phase I study of a ^99mTc-labeled anti–programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non–small cell lung cancer. J Nucl Med. 2019;60(9):1213-20. https://doi.org/10.2967/jnumed.118.224170.CrossRefPubMedPubMedCentral

55.

Miao Y, Lv G, Chen Y, Qiu L, Xie M, Lin J. One-step radiosynthesis and initial evaluation of a small molecule PET tracer for PD-L1 imaging. Bioorg Med Chem Lett. 2020;30(24): 127572. https://doi.org/10.1016/j.bmcl.2020.127572.CrossRefPubMed

56.

Huang H, Zhu H, Li G, Xie Q, Yang X, Xu X, et al. Construction of Anti-hPD-L1 HCAb Nb6 and in situ ¹²⁴I labeling for noninvasive detection of PD-L1 expression in human bone sarcoma. Bioconj Chem. 2019;30(10):2614–23. https://doi.org/10.1021/acs.bioconjchem.9b00539.CrossRef

57.

Jiang J, Zhang M, Li G, Liu T, Wan Y, Liu Z, et al. Evaluation of ⁶⁴Cu radiolabeled anti-hPD-L1 Nb6 for positron emission tomography imaging in lung cancer tumor mice model. Bioorg Med Chem Lett. 2020;30(4): 126915. https://doi.org/10.1016/j.bmcl.2019.126915.CrossRefPubMed

58.

Huang H, Zhu H, Xie Q, Tian X, Yang X, Feng F, et al. Evaluation of ¹²⁴I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice. Acta Pharmaceutica Sinica B. 2020;10(7):1321–30. https://doi.org/10.1016/j.apsb.2020.02.004.CrossRefPubMedPubMedCentral

59.

Zhou X, Jiang J, Yang X, Liu T, Ding J, Nimmagadda S, et al. First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET. J Nucl Med. 2021:jnumed.121.262045. https://doi.org/10.2967/jnumed.121.262045.

60.

Gan Q, Zhang X, Ruan Q, Fang Sa, Zhang J. ^99mTc-CN7DG: a highly expected SPECT imaging agent of cancer with satisfactory tumor uptake and tumor-to-nontarget ratios. Mol Pharm. 2021;18(3):1356–63. https://doi.org/10.1021/acs.molpharmaceut.0c01177.

61.

Zhang X, Ruan Q, Jiang Y, Gan Q, Zhang J. Evaluation of ^99mTc-CN5DG as a broad-spectrum SPECT probe for tumor imaging. Transl Oncol. 2021;14(1): 100966. https://doi.org/10.1016/j.tranon.2020.100966.CrossRefPubMed

62.

Zhang X, Ruan Q, Duan X, Gan Q, Song X, Fang S, et al. Novel ^99mTc-labeled glucose derivative for single photon emission computed tomography: a promising tumor imaging agent. Mol Pharm. 2018;15(8):3417–24. https://doi.org/10.1021/acs.molpharmaceut.8b00415.

63.

Liu H, Han Y, Li J, Qin M, Fu Q, Wang C, et al. ¹⁸F-alanine derivative serves as an ASCT2 marker for cancer imaging. Mol Pharm. 2018;15(3):947–54. https://doi.org/10.1021/acs.molpharmaceut.7b00884.

64.

Li C, Liu H, Duan D, Zhou Z, Liu Z. Preclinical study of an ¹⁸F-labeled glutamine derivative for cancer imaging. Nucl Med Biol. 2018;64–65:34–40. https://doi.org/10.1016/j.nucmedbio.2018.06.007.CrossRefPubMed

65.

Li Z, Kong Z, Chen J, Li J, Li N, Yang Z, et al. ¹⁸F-Boramino acid PET/CT in healthy volunteers and glioma patients. Eur J Nucl Med Mol Imaging. 2021;48:3113-21. https://doi.org/10.1007/s00259-021-05212-7.CrossRefPubMedPubMedCentral

66.

Sun A, Liu S, Tang X, Pan Q, Zhang Z, Ma H, et al. N-(2–¹⁸F-fluoropropionyl)-l-glutamate as a potential oncology tracer for PET imaging of glioma. Appl Radiat Isot. 2021;168: 109530. https://doi.org/10.1016/j.apradiso.2020.109530.CrossRefPubMed

67.

Luo Z, Zhu H, Lin X, Hong Y, Xiao S, Zhang Q, et al. Radio-labelling and micro-PET study of ⁶⁴Cu Labelled PnAO-1-(2-nitroimidazole) for hypoxia imaging. Chemical Journal of Chinese Universities. 2015;36(1):87–92 (in Chinese). https://doi.org/10.7503/cjcu20140438.CrossRef

68.

Luo Z, Zhu H, Lin X, Chu T, Luo R, Wang Y, et al. Synthesis and radiolabeling of ⁶⁴Cu-labeled 2-nitroimidazole derivative ⁶⁴Cu-BMS2P2 for hypoxia imaging. Bioorg Med Chem Lett. 2016;26(5):1397–400. https://doi.org/10.1016/j.bmcl.2016.01.077.CrossRefPubMed

69.

Yang X, Wang F, Zhu H, Yang Z, Chu T. Synthesis and bioevaluation of novel [¹⁸F]FDG-conjugated 2-nitroimidazole derivatives for tumor hypoxia imaging. Mol Pharm. 2019;16(5):2118–28. https://doi.org/10.1021/acs.molpharmaceut.9b00075.CrossRefPubMed

70.

Xu Q, Zhu C, Xu Y, Pan D, Liu P, Yang R, et al. Preliminary evaluation of [¹⁸F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET. J Drug Targeting. 2015;23(9):813–20. https://doi.org/10.3109/1061186X.2015.1020808.CrossRef

71.

Zhang P, Zhao Z, Zhang L, Wu W, Xu Y, Pan D, et al. [⁶⁸Ga]Ga-NOTA-MAL-Cys39-exendin-4, a potential GLP-1R targeted PET tracer for the detection of insulinoma. Nucl Med Biol. 2019;74–75:19–24. https://doi.org/10.1016/j.nucmedbio.2019.08.002.CrossRefPubMed

72.

Gao F, Peng C, Zhuang R, Guo Z, Liu H, Huang L, et al. ¹⁸F-labeled ethisterone derivative for progesterone receptor targeted PET imaging of breast cancer. Nucl Med Biol. 2019;72–73:62–9. https://doi.org/10.1016/j.nucmedbio.2019.07.001.CrossRefPubMed

73.

Zhong Y, Yang S, Cui J, Wang J, Li L, Chen Y, et al. Novel ¹⁸F-labeled isonicotinamide-based radioligands for positron emission tomography imaging of glycogen synthase kinase-3β. Mol Pharm. 2021;18(3):1277–84. https://doi.org/10.1021/acs.molpharmaceut.0c01133.CrossRefPubMed

74.

Li X, Hu K, Liu W, Wei Y, Sha R, Long Y, et al. Synthesis and evaluation of [¹⁸F]FP-Lys-GE11 as a new radiolabeled peptide probe for epidermal growth factor receptor (EGFR) imaging. Nucl Med Biol. 2020;90–91:84–92. https://doi.org/10.1016/j.nucmedbio.2020.10.004.CrossRefPubMed

75.

Wang Y, Li M, Zhang Y, Zhang F, Liu C, Song Y, et al. Detection of melanoma metastases with PET—comparison of ¹⁸F–5-FPN with 18F–FDG. Nucl Med Biol. 2017;50:33–8. https://doi.org/10.1016/j.nucmedbio.2017.03.005.CrossRefPubMed

76.

Qiu L, Tan H, Lin Q, Si Z, Mao W, Wang T, et al. A pretargeted imaging strategy for immune checkpoint ligand Pd-L1 expression in tumor based on bioorthogonal Diels-Alder click chemistry. Mol Imag Biol. 2020;22(4):842–53. https://doi.org/10.1007/s11307-019-01441-3.CrossRef

77.

Wu Y, Li L, Dong C, Wang F. Small-animal SPECT/CT imaging with 99mTc-HYNIC-H10F detects HER2 expression in mice bearing human breast cancers. J Nucl Med. 2016;57(supplement 2):1162. https://jnm.snmjournals.org/content/57/supplement_2/1162. Accessed 8 Nov 2021.

78.

Fu Z, Lin Q, Hu B, Zhang Y, Chen W, Zhu J, et al. P2X7 PET Radioligand ¹⁸F-PTTP for differentiation of lung tumor from inflammation. J Nucl Med. 2019;60(7):930-6. https://doi.org/10.2967/jnumed.118.222547.CrossRefPubMedPubMedCentral

79.

Zhang D, Zhuang R, Guo Z, Gao M, Huang L, You L, et al. Desmin- and vimentin-mediated hepatic stellate cell-targeting radiotracer ^99mTc-GlcNAc-PEI for liver fibrosis imaging with SPECT. Theranostics. 2018;8(5):1340–9. https://www.thno.org/v08p1340.htm. Accessed 8 Nov 2021.

80.

Sun P, Zhu Y, Han Y, Hu K, Huang S, Wang M, et al. Radiosynthesis and biological evaluation of an fluorine-18 labeled galactose derivative [¹⁸F]FPGal for imaging the hepatic asialoglycoprotein receptor. Bioorg Med Chem Lett. 2020;30(12): 127187. https://doi.org/10.1016/j.bmcl.2020.127187.CrossRefPubMed

81.

Zhu H, Zhang H, Zhou N, Ding J, Jiang J, Liu T, et al. Molecular PET/CT profiling of ACE2 expression in vivo: implications for infection and outcome from SARS-CoV-2. Adv Sci. 2021;8(16):2100965. https://doi.org/10.1002/advs.202100965.CrossRef

82.

Chen J, Li C, Hong H, Liu H, Wang C, Xu M, et al. Side chain optimization remarkably enhances the in vivo stability of ¹⁸F-labeled glutamine for tumor imaging. Mol Pharm. 2019;16(12):5035–41. https://doi.org/10.1021/acs.molpharmaceut.9b00891.

83.

Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, et al. Peptide receptor radionuclide therapy of late-stage neuroendocrine tumor patients with multiple cycles of ¹⁷⁷Lu-DOTA-EB-TATE. J Nucl Med. 2021:62(3):386-92. https://doi.org/10.2967/jnumed.120.248658.

84.

Deng X, Li H, Ye Z, Guo H, Li F, Luo Z. Radiolabeling and biodistribution of ¹⁷⁷Lu-EDTMP and ¹⁷⁷Lu-DOTMP. Journal of Isotopes. 2009;22(2):71–5 (in Chinese). http://www.tws.org.cn/CN/volumn/volumn_1150.shtml#1. Accessed 8 Nov 2021.

85.

Li H, Liang J, Xiang X, Deng X, Zheng D, Luo H. Biodistribution and imaging study on ¹⁷⁷Lu-EDTMP prepared by kit method. Journal of Isotopes. 2010;23(2):65–70 (in Chinese). http://www.tws.org.cn/CN/10.7538/tws.2010.23.02.0065. Accessed 8 Nov 2021.

86.

Yuan J, Liu C, Liu X, Wang Y, Kuai D, Zhang G, et al. Efficacy and safety of ¹⁷⁷Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase ii study. Clin Nucl Med. 2013;38(2):88-92. https://doi.org/10.1097/RLU.0b013e318279bf4d.

87.

Ma X, Zhang J, Li H, Liang J, Yang Y, Yang C. Preparation and preliminary biological evaluation of ¹⁷⁷Lu labelled rituximab. Journal of Isotopes. 2014;27(2):98–103 (in Chinese). http://www.tws.org.cn/CN/Y2014/V27/I2/98. Accessed 8 Nov 2021.

88.

Ren J, Xu M, Chen J, Ding J, Wang P, Huo L, et al. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a ¹⁷⁷Lu-labeled αPD-L1 antibody. Theranostics. 2021;11(1):304–15. https://doi.org/10.7150/thno.45540.CrossRefPubMedPubMedCentral

89.

Liu Z, Ma T, Liu H, Jin Z, Sun X, Zhao H, et al. ¹⁷⁷Lu-labeled antibodies for EGFR-targeted SPECT/CT Imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. Mol Pharm. 2014;11(3):800–7. https://doi.org/10.1021/mp4005047.CrossRefPubMed

90.

Targeted alpha therapy working g. targeted alpha therapy, an emerging class of cancer agents: a review. JAMA Oncology. 2018;4(12):1765–72. https://doi.org/10.1001/jamaoncol.2018.4044.

91.

Liu N, Yang Y, Zan L, Liao J, Jin J. Astatine-211 labeling of insulin: synthesis and preliminary evaluation in vivo and in vitro. J Radioanal Nucl Chem. 2007;272(1):85–90. https://doi.org/10.1007/s10967-006-6781-8.CrossRef

92.

Liu W, Ma H, Tang Y, Chen Q, Peng S, Yang J, et al. One-step labelling of a novel small-molecule peptide with astatine-211: preliminary evaluation in vitro and in vivo. J Radioanal Nucl Chem. 2018;316(2):451–6. https://doi.org/10.1007/s10967-018-5780-x.CrossRef

93.

Zhao B, Qin S, Chai L, Lu G, Yang Y, Cai H, et al. Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment. Biorg Med Chem. 2018;26(5):1086–91. https://doi.org/10.1016/j.bmc.2018.01.023.CrossRef

Titel: Current status and future perspective of radiopharmaceuticals in China
verfasst von: Ji Hu
Hongyu Li
Yanying Sui
Jin Du
Publikationsdatum: 12.11.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05615-6

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

Identifying the individual metabolic abnormities from a systemic perspective using whole-body PET imaging

Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study

Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma

Synthesis, preclinical evaluation, and first-in-human study of Al18F-PSMA-Q for prostate cancer imaging

Advances in aptamer-based nuclear imaging

Deep learning signatures reveal multiscale intratumor heterogeneity associated with biological functions and survival in recurrent nasopharyngeal carcinoma